AI assistant
Evotec SE — Capital/Financing Update 2012
Jul 10, 2012
151_rns_2012-07-10_f9afeb46-e5d1-412b-9ee5-c2574be1df3c.html
Capital/Financing Update
Open in viewerOpens in your device viewer
News Details
Ad-hoc | 10 July 2012 07:09
CureBeta, a collaboration between Evotec AG and Harvard University enters strategic alliance with Janssen Pharmaceuticals
Evotec AG / Key word(s): Contract
10.07.2012 07:09
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard,
ISIN: DE 000 566480 9, WKN 566480) today announced that it has entered into
a license and collaboration agreement with Janssen Pharmaceuticals, Inc.
with a particular focus on the regeneration of insulin- producing beta
cells. The agreement gives Janssen Pharmaceuticals exclusive access to a
selected portfolio of small molecules and biologics research programs.
The agreement between Evotec and Janssen triggers an upfront payment of US
$8 million. Upon achievement of certain pre-clinical, clinical, regulatory
and commercial goals, Janssen would make future milestone payments, of up
to a total of about US $200 million to US $300 million per product. In
addition, Janssen will pay royalties on future sales of any products that
result from this collaboration. The upfront, milestone and royalty payments
will be shared by Evotec and Harvard according to pre-agreed terms. Evotec
will receive additional research support for discovery and early
development work that will be conducted in collaboration with Janssen.
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred
Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560
81-242, [email protected]
10.07.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service